ADVERTISEMENT

Early triple-negative breast cancer: what are the best therapies?

Miriam Davis, PhD   |   Clinical Summary   |   03 January 2023
ADVERTISEMENT

Takeaway

  • A network meta-analysis was used to compare adjuvant therapies for early-stage (stages I-III) resected triple-negative breast cancer (TNBC).
  • It finds that only 1 regimen—the addition of capecitabine to anthracycline and taxane-based chemotherapy—is effective for OS.
  • 6 regimens are found to be most effective for DFS, with carboplatin/paclitaxel coming out...

          

Topic Challenges

left
right